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Reply
We appreciate the comments of Dr. Spodick on our study (1). We
agree that atrial fibrillation is uncommonly associated with pericarditis,
but we believe that there is a relationship between these two conditions
in some patients. Many investigators in this field (2–7) also recognize
such an association between atrial fibrillation and pericarditis. In a
704-patient study by Davidson et al. (7), pericarditis was reported as
the only identifiable condition association with atrial fibrillation in 5
patients (0.7%). We found a similar magnitude of association (3 of 356
patients, 0.8%) in our study. In one of our patients, there was also a
history of systemic hypertension, a disorder more commonly associated
with atrial fibrillation. In the other two patients (a 27-year old man and
a 71-year old woman), no other underlying condition was identified.
Given the low incidence of atrial fibrillation with pericarditis, we agree
with Dr. Spodick that, for these patients, exclusion of occult cardiac
disease is also prudent.
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Interstitial Fibrosis and Angiotensin-
Converting Enzyme Inhibition in Patients
With End-Stage Myocardial Infarction
Marijianowski et al. (1) have recently investigated the collagen content
of noninfarcted myocardium in patients with end-stage myocardial
infarction. They report that total collagen levels and collagen type I/III
ratios did not differ statistically from those in reference hearts of
patients who died of noncardiovascular-related disease. This outcome
contrasts with other studies in humans (2–6) and experimental animals
(7–10), which have demonstrated an increased interstitial fibrosis in
the remote myocardium after infarction and its contribution in the
impairment of systolic and diastolic ventricular function (11). How-
ever, all patients enrolled in the study of Marijianowski et al. (1) had
been treated with angiotensin-converting enzyme (ACE) inhibitors
(among other medications), which are known to cause an attenuation
of fibrogenesis (3,7,9). Therefore, it is hard to understand that the
authors consider it unlikely that ACE inhibition had been truly
effective on interstitial fibrosis. Their consideration is based on the
argument that other criteria of ventricular remodeling (“extensive
myocardial scar formation, with compensatory hypertrophy of viable
myocardium and global LV dilation”) were still present in these
patients.
No quantitative analysis or comparison of these “other criteria” has
been presented in this study. Also, it is questionable if, and to what
extent, the attenuation of fibrogenesis by ACE inhibition parallels its
effects on myocyte hypertrophy during the development of heart
failure: the triggers for an increase of interstitital collagen and for
myocyte hypertrophy are not the same under all circumstances (4,12)
and vice versa the effects of ACE inhibition differ in both processes
(12). Finally, we would like to comment upon the authors’ interpreta-
tion of the results obtained by other groups (see their Discussion). In
response to our own study (4), their qualification of microscopic
collagenous patches (our Fig. 1A) as “replacement fibrosis” indicative
of extended scarring is incorrect for at least two reasons: (1) we
excluded such extensions into our noninfarcted myocardial samples
microscopically and (2) even if present, isolated microscopic patches of
fibrosis are more likely caused by myocyte necrosis due to other
mechanisms (13,14).
In conclusion, we regard the results reported by Marijianowski et
al. (1) as new evidence that treatment with ACE inhibitors leads to an
attenuated interstitial fibrosis in noninfarcted myocardium of patients
with (end-stage) myocardial infarction.
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Reply
We appreciate the commentary provided by Drs. Volders and Daemen
regarding our work on postinfarct ventricular remodeling (1).
The crux of their critique relates to the fact that our observations
deny the widely accepted concept that postinfarct myocardial hyper-
trophy, as an adaptive phenomenon to the loss of working myocar-
dium, is associated with interstitial fibrosis per se. This concept has led
to the inevitable conclusion that the clinical phenomenon of progres-
sive heart failure is because of the increase in extracellular matrix
components. Our observations reveal that this sequence of events is
not necessarily true. Indeed, the patients reported in our study all
presented clinically with progressive heart failure, which necessitated
heart transplantation as the only remedy and, interestingly, neither one
of these individuals had a significant increase in interstitial fibrous
tissue in the noninfarcted hypertrophied myocardium. Hence, the
message is that postinfarct remodeling in our patients is not associated
with interstitial fibrosis, despite progressive clinical deterioration.
It appears as if Drs. Volder and Daemen wish to ignore the fact
that the clinical condition deteriorated despite absence of interstitial
fibrosis in the noninfarcted myocardium. Instead, they focus on the
potential role of angiotensin-converting enzyme (ACE) inhibitors to
“explain” the lack of fibrosis, an aspect that we dealt with in the
paragraph “Study limitations.” It is of interest that otherwise Drs.
Volders and Daemen provide no data to contradict our observations.
Thus, we are left with the impression that Drs. Volders and Daemen
are biased by their own studies on this subject. Be that as it may, if the
use of ACE inhibitors in our patients does account for the lack of
interstitial fibrosis in the noninfarcted myocardium, the search for
tools to prevent an increase in extracellular matrix and, hence, clinical
deterioration is not necessarily the solution in patients with postinfarct
myocardial remodeling. This is precisely the point made in our final
paragraph.
ANTON E. BECKER, MD, FACC
Department of Cardiovascular Pathology
Academic Medical Center
Meibergdreef 9
1105 AZ Amsterdam, The Netherlands
E-mail: m.i.schenker@amc.uva.nl
MONIQUE M.M.H. MARIJIANOWSKI, PHD
Department of Medicine
Emory University School of Medicine
1364 Clifton Road NE
Alanta, Georgia 30322
Reference
1. Marijianowski MMH, Teeling P, Becker AE. Remodeling after myocardial infarction in
humans is not associated with interstitial fibrosis of noninfarcted myocardium. J Am Coll
Cardiol 1997;30:76–82.
Does Earthquake-Induced Cardiovascular
Disease Persist or Is It Suppressed After the
Major Quake?
We have read the article of Koner et al. (1) with great interest, because
their findings that cardiovascular events were suppressed during the 2
weeks following the Northridge earthquake differed from our study on
the Hanshin–Awaji earthquake. In our study based on the death
information directly obtained from physicians with a 98% response
rate, the increase in the cardiovascular events (both cerebrovascular
and coronary events) persisted after the major quake for at least a few
months (2,3). Coronary artery disease death persisted for 3 weeks after
the quake, whereas the stroke death persisted for 5 weeks (Table 1).
This discrepancy might in part be due to the degree of stress and the
subsequent environmental change in the study subjects. In our study,
the subjects were living in one of the most heavily damaged areas,
including the epicenter. The study of Kloner et al. (1) included the
subjects living in relatively less damaged areas surrounding the epi-
center. In addition, the proportion of the elderly subjects in the study
area might have affected the different results. We included more
elderly subjects in our study because our study region was a community
with a large elderly population (31% of the total of 64,000 residents
were 60 years old or more). Elderly subjects living in the most damaged
area may be more prone to cardiovascular events for a long time after
the quake. To clarify the speculation of Kloner et al. (1) that overcom-
pensation may suppress subsequent cardiovascular deaths after a quake, it
is necessary to limit the study population to the subpopulation living in the
most heavily damaged area, especially the elderly population aged 60
years old or more.
Another very interesting difference was that the stroke death did
not increase after the Northridge earthquake. This might be due to the
racial differences in the stress-induced phenotype of cardiovascular
disease between whites and Japanese. In Japanese, coronary artery
disease is much less frequent and stroke is more common, when
compared with whites (4). Thus, extreme stress, such as a major
earthquake, might trigger cerebrovascular events in Japanese and
coronary events in whites. Concurring the stroke death, there might be
some delay between the onset and death. Therefore, for Kloner et al.
Table 1. Incidence of Cardiovascular Death in the Tsuna Region
after the 1995 Hanshin–Awaji Earthquake
January* February March April
Total
(Jan.–Apr.)
Coronary artery disease 13 (9) 15 (4) 10 (14) 7 (4) 45 (31)
Acute myocardial
infarction
11 (0) 4 (3) 8 (2) 5 (1) 28 (6)
Sudden death 2 (9) 11 (1) 2 (12) 2 (3) 17 (25)
Stroke 9 (3) 25 (10) 15 (7) 9 (11) 58 (31)
Cerebral infarction 7 (2) 19 (5) 8 (2) 7 (6) 41 (15)
Cerebral hemorrhage 2 (1) 3 (2) 5 (2) 1 (3) 11 (8)
Subarachnoid hemorrhage 0 (0) 1 (1) 2 (1) 1 (2) 4 (4)
Unclassified stroke 0 (0) 2 (2) 0 (2) 0 (0) 2 (4)
All cardiovascular disease 22 (12) 40 (14) 25 (21) 16 (15) 103 (62)
Parentheses indicate the number of cardiovascular deaths in 1994. *January
17–31.
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